Visugromab
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Product Specifications
CAS Number
2556646-63-8
Product Name Alternative
CTL-002
UNSPSC
12352203
Target
PD-1/PD-L1; TGF-beta/Smad
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/visugromab.html
Purity
98.40
Solubility
10 mM in DMSO|H2O
Smiles
[Visugromab]
Molecular Weight
(144.56 kDa)
References & Citations
[1]Necchi A, et al. Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC) : A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER) [J]. 2023.|[2]Melero I, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan;637 (8048) :1218-1227.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
